We want to make a difference to people with rare diseases. By working closely with patients and their relatives we learn about their daily challenges and needs.

Swedish Orphan Biovitrum (SOBI) is a leading European specialty pharmaceutical company, based in Stockholm, Sweden. It is a leading integrated biopharmaceutical company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients and their families. SOBI is focused on providing and developing specialty pharmaceuticals for patients with rare diseases and significant medical needs.

The portfolio comprises about 60 marketed products, as well as projects in late clinical phases. Key therapeutic areas are hematological diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic oncology. Their vision is to be an exciting and leading international rare disease pharmaceutical company. SOBI has been involved in the development and manufacturing of recombinant protein drugs since the technology was first developed more than 30 years ago.

Sobi sales and marketing organization covers about 20 countries in Europe and a subsidiary in the US. They are also represented through partners in in the Middle East, Australia and New Zealand.